TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05957484

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational brainstem neuromodulation device
Description: This study device is non-invasive meaning it stays outside of the body. It stimulates activity in the brain through a headset with metallic earpieces that fit into the participant's ear canals. The device will be loaded with certain neurostimulation pattern, and the earpieces will provide the stimulation at the prescribed pattern.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational brainstem neuromodulation device
Description: This study device is non-invasive meaning it stays outside of the body. It stimulates activity in the brain through a headset with metallic earpieces that fit into the participant's ear canals. The device will be loaded with certain neurostimulation pattern, and the earpieces will provide the stimulation at the prescribed pattern.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Investigational brainstem neuromodulation device
Description: This study device is non-invasive meaning it stays outside of the body. It stimulates activity in the brain through a headset with metallic earpieces that fit into the participant's ear canals. The device will be loaded with certain neurostimulation pattern, and the earpieces will provide the stimulation at the prescribed pattern.
Study: NCT06341296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome
Description: 70 mg/m\^2 , d1, 14 days per cycle, 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400mg/m\^2, then 2400mg/m\^2, continuous intravenous infusion for 46-48h, d1-2, 14 days per cycle, 8 cycles.
Study: NCT03281681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-083, Dianhydrogalactitol
Description: VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
Study: NCT06132893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken once daily
Study: NCT05433662

Intervention type: BEHAVIORAL
Intervention: Pandemic Acceptance and Commitment Therapy (Pan-ACT)
Description: Pan-ACT is a 10-session, closed group, transdiagnostic intervention for older adults.
Study: NCT06241313

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atogepant
Description: Oral Tablet
Study: NCT06341296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: 400mg/m\^2, d1, 14 days per cycle, 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg, d1, 14 days per cycle, 8 cycles.
Study: NCT06241313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet
Study: NCT03686306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet / Direct Oral Anticoagulant + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk.
Study: NCT06241313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atogepant
Description: Oral Tablet
Study: NCT06161558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Small-molecule tyrosine kinase inhibitor targeting EGFR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Small-molecule tyrosine kinase inhibitor targeting EGFR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Small-molecule tyrosine kinase inhibitor targeting VEGFR1, VEGFR2, and VEGFR3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Small-molecule tyrosine kinase inhibitor targeting VEGFR1, VEGFR2, and VEGFR3
Study: NCT06477653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Dupilumab is an interleukin-4 receptor alpha antagonist. Dosing for an individual will be determined based on the nature of their residual symptoms and the FDA-approved dosing for that indication.
Study: NCT06052618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib is administered orally as 200 mg twice daily for a total of 6, 28-day cycles
Study: NCT04729959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample and tumor tissue collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample and tumor tissue collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Undergo FSRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Undergo FSRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Undergo FSRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV
Study: NCT04294901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct to patient medication brochure
Description: An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct to patient medication brochure
Description: An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct to patient medication brochure
Description: An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.
Study: NCT05475743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Informed Movement program
Description: The patients included in the experimental group attended an 8-week Pain Informed Movement program in addition to standard medical care. The program was led by a physical therapist with experience in treating patients with chronic pain. This program consisted of 2 face-to-face sessions per week, and they were asked to complete two sessions at home weekly. The first face-to-face session was a group session with 3-6 participants, and the second face-to-face session was individual. Both sessions lasted approximately 1 h. In the group sessions, pain neuroscience education was conducted. In the individual sessions, an individualized functional exercise program was performed by each patient, as well as relaxation techniques. Patients were asked to perform the functional exercises and relaxation techniques at home. Participants were asked to record their compliance with the program and their progress.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care and leaflet education
Description: In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
Study: NCT05646706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Study: NCT05655312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [203Pb]VMT01
Description: \[203Pb\]VMT01 is administered intravenous (IV) as an imaging agent for SPECT/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [203Pb]VMT01
Description: \[203Pb\]VMT01 is administered intravenous (IV) as an imaging agent for SPECT/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [203Pb]VMT01
Description: \[203Pb\]VMT01 is administered intravenous (IV) as an imaging agent for SPECT/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [203Pb]VMT01
Description: \[203Pb\]VMT01 is administered intravenous (IV) as an imaging agent for SPECT/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT01
Description: Subjects with positive uptake of \[203Pb\]VMT01 will receive a fixed dose of \[212Pb\]VMT01 administered IV every 8 weeks starting at Cycle 1 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT01
Description: Subjects with positive uptake of \[203Pb\]VMT01 will receive a fixed dose of \[212Pb\]VMT01 administered IV every 8 weeks starting at Cycle 1 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT01
Description: Subjects with positive uptake of \[203Pb\]VMT01 will receive a fixed dose of \[212Pb\]VMT01 administered IV every 8 weeks starting at Cycle 1 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT01
Description: Subjects with positive uptake of \[203Pb\]VMT01 will receive a fixed dose of \[212Pb\]VMT01 administered IV every 8 weeks starting at Cycle 1 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For all combination-therapy cohorts, 480 mg nivolumab will be administered every 4 weeks as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For all combination-therapy cohorts, 480 mg nivolumab will be administered every 4 weeks as an IV infusion.
Study: NCT06295809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V940
Description: IM injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Local resection of cancerous lesions of the skin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Local resection of cancerous lesions of the skin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Local resection of cancerous lesions of the skin
Study: NCT06269640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Septal Scoring Along Midline Endocardium
Description: Transcatheter ventricular myotomy called SEptal Scoring Along the Midline Endocardium (SESAME) that relies on intramyocardial guidewire navigation and transcatheter electrosurgery
Study: NCT04781140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg SPN-812
Description: 100mg SPN-812 will be administered once daily and compared to Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once daily
Study: NCT04548752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05923190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enfortumab vedotin
Description: EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered on day 1 of a 21-day cycle
Study: NCT05381519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DXP604
Description: 1800mg，IVgtt

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DXP604
Description: 1800mg，IVgtt
Study: NCT04694937

Intervention type: DEVICE
Intervention: heart rate variabilty measured by pulse oximetry
Description: Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.~HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points.

Intervention type: DEVICE
Intervention: heart rate variabilty measured by pulse oximetry
Description: Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.~HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points.
Study: NCT06322121

Intervention type: OTHER
Intervention: MRI
Description: Assessment of vascular reactivity and CAA/SVD MRI markers
Study: NCT05815160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123
Description: Administered as capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered as IV infusion.
Study: NCT04977986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYN002 - transdermal gel
Description: Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery)~Other Names:~Placebo Comparator Matching Placebo
Study: NCT06161545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: 400 mg administered as a 30 minute IV infusion on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: 400 mg administered as a 30 minute IV infusion on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 15 ug/kg via subcutaneous injection on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 15 ug/kg via subcutaneous injection on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK cells
Description: Irradiated PD-L1 t-haNK cells at a dose of 2 x 10\^9 administered via IV infusion over 30 minutes on Days 1, 5, 8, 12, and 15
Study: NCT06471751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory and Oropharyngeal Muscle Strengthening
Description: Patients will conduct the training at home, 5 days a week for 3 months. They will perform 2 sets of 30 inspirations against resistance (POWERbreathe® K5 , Powerbreathe International Limited, UK), equal to 70% Maximum Inspiratory Pressure (MIP). Patients will be guided for oropharyngeal exercises.~The sessions will be supervised by the investigator every 3 weeks. During sessions with the investigator, sessions recorded in the device will be downloaded to verify compliance. A MIP measurement will be performed to adjust the resistance of the device.
Study: NCT05340062

Intervention type: DEVICE
Intervention: bedside sonography
Description: TCD and ONSD sonography twice a day per 2 days
Study: NCT04447911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Empagliflozin 25mg per os once daily for 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo per os once daily for 30 days
Study: NCT06447272

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham inspiratory muscle training
Description: This group will receive conventional treatment + sham IMT (with 10% MIP as the training intensity)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: target inspiratory muscle training
Description: This group will receive conventional treatment + target IMT (the IMT identified as optimal intensity based on the results of our undergoing study).